



Received on 01 March 2019; received in revised form, 20 September 2021; accepted, 01 October 2021; published 01 November 2021

HPTLC METHOD DEVELOPMENT AND VALIDATION FOR THE *IN-VITRO* INTERACTION STUDY OF MEBENDAZOLE WITH ATORVASTATIN

Tresa Thomas^{*}, A. Manohari and T. K. Ravi

Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore - 641 044, Tamil Nadu, India.

Keywords:

High-performance thin-layer chromatography, *In-vitro* interaction study, Mebendazole, Atorvastatin, protein binding, validation

Correspondence to Author:

A. Manohari

Assistant Professor,
Sri Ramakrishna Institute of
Paramedical Sciences, Coimbatore -
641 044, Tamil Nadu, India.

E-mail: manohariphyto@gmail.com

ABSTRACT: By HPTLC method, a mobile phase system comprising of Ethyl acetate: Toluene: Methanol (5:4:1v/v/v) was selected, and the detection was carried out at 280nm. The R_f values were found to be 0.65 ± 0.03 and 0.27 ± 0.03 for Mebendazole and Atorvastatin, respectively, which showed a good separation. The method was validated as per ICH guidelines. The percentage RSD values of repeatability, intraday, and interday were found to be less than 2 prove the precision of the method. The correlation coefficient value from the calibration graph was found to be 0.9949 for Mebendazole and 0.9979 for Atorvastatin. The percentage protein binding of Mebendazole and Atorvastatin was estimated by the equilibrium dialysis method. The *in-vitro* displacement interaction study was carried out using standard solutions of a mixture containing 1.5×10^{-4} M Mebendazole and Atorvastatin along with 1.5×10^{-4} M BSA. The percentage protein binding of individual Mebendazole and Atorvastatin after 6hr was found to be 86.14% and 91.18% respectively. While they were evaluated in the presence of each other, the percentage protein binding was found as 84.4% for Mebendazole and 94.8% for Atorvastatin at the end of the study. The percentage protein binding of Mebendazole decreased by 1.74% and increased for Atorvastatin by 3.62%.

INTRODUCTION: Mebendazole (Methyl N-(6-benzoyl-1H-1, 3-benzodiazol-2-yl) carbamate) is an antihelminthic drug having molecular formula $C_{16}H_{13}N_3O_3$. Mebendazole causes degenerative alterations in the tegument and intestinal cells of the worm, which leads to diminished energy production; the parasite is immobilized and eventually dies²⁰. Atorvastatin ((3R, 5R)-7-[2-(4-fluorophenyl) - 3 - phenyl - 4 - (phenylcarbamoyl) - 5 - (propan - 2 - yl) - 1H - pyrrol - 1 - yl] - 3, 5-dihydroxyheptanoic acid) is a statin group of drug with molecular formula $C_{33}H_{35}FN_2O_5$.

Atorvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase. Atorvastatin also reduces VLDL-C, serum triglycerides (TG), and Intermediate Density Lipoproteins (IDL), as well as the number of apolipoprotein B (apo B) containing particles, but increases High-Density Lipoprotein Cholesterol²¹. Literature survey revealed that there is no reported HPTLC method for the *in-vitro* drug interaction of Mebendazole with Atorvastatin.


Hence, the aim and objective of the present work is the development and validation for the separation of Mebendazole and Atorvastatin and the application of the developed HPTLC method for protein binding based *in-vitro* interaction Mebendazole with Atorvastatin. Drug-drug interactions are pervasive in poly-drug prescription. Clinical case reports or studies are reported from time to time as evidence of interaction between drugs. Several studies explained such interaction at

QUICK RESPONSE CODE 	DOI: 10.13040/IJPSR.0975-8232.12(11).5860-66
	This article can be accessed online on www.ijpsr.com
DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.12(11).5860-66	

the molecular and enzyme level so that the relationship between clinical and experimental research shall be recognized. There are many approaches practiced for *in-vitro* drug interaction study such as metabolism-based, protein binding, etc. Protein binding plays a major role in the bioavailability of the drugs.

Distribution interaction studies between drugs involve interaction in the protein binding of two drugs. Protein binding interactions are displacement reactions, which have been concerned as the mechanisms in many drug-drug interactions.

The extent of drug binding to plasma proteins, determined by measuring the free active fraction, has a significant effect on the pharmacokinetics and pharmacodynamics of a drug.



MATERIALS AND METHODS:

Instrumentation: Camag HPTLC system (with TLC Scanner-3, Win CATS software and Linomat 5 as application device) was used for the method development and *in-vitro* interaction study.

Reference Substances, Reagents and Chemicals:

Mebendazole and Atorvastatin were purchased from Sigma Aldrich, India. All the chemicals and solvents used were supplied by S. D. Fine Chemicals Ltd., Sigma Aldrich, and Merck India Ltd. Pre-coated silica gel 60F254 on aluminium sheets were procured from Merck, Germany.

Chromatographic Conditions: Pre-coated silica gel 60 F₂₅₄ aluminum sheets (10 x10 cm) as the stationary phase, an analytical balance was used for weighing the compounds, plates were scanned using Camag win CATS software, bandwidth was 6 mm using Hamilton 100 µl syringe on pre-coated plates using automatic application device, Linear ascending development was carried out in twin trough glass chamber, and densitometric scanning

was performed on Camag TLC scanner III in the absorption mode at 280 nm and operated by win CATS software.

Solution Preparation:

Preparation of Standard Stock Solution: About 2mg of Mebendazole and 4mg of Atorvastatin were accurately weighed and transferred to 50 ml of volumetric flask and sonicated for 20 minutes to dissolve the sample.

Then the volume was made up with methanol to obtain a concentration of 40µg/ml of Mebendazole and 80µg/ml of Atorvastatin.

Preparation of Phosphate Buffer pH 7.4: The Phosphate buffer was prepared by taking 62.5 ml of 0.2M potassium dihydrogen phosphate and added with 48.8 ml Sodium hydroxide. It was made up to 250 ml with distilled water.

Preparation of Bovine Serum Albumin Solution (1.5×10⁻⁴ M): The Bovine serum albumin (BSA) solution was employed for the estimation of protein binding of the drugs. To prepare 1.5×10⁻⁴ M BSA solution, 0.48g of BSA was dissolved in distilled water and made upto 50 ml.

Activation of Dialysis Membrane Tubes: The dialysis membrane tubes were cut into each 13cm length, and its activation was done by boiling the membrane for 2 h in 250ml of distilled water at 70 °C (±5 °C). The boiled membranes were washed thoroughly with fresh distilled water and utilized for the study.

Preparation of Standard Solution of Mebendazole (1.5×10⁻⁴ M): A quantity of about 4 mg of Mebendazole was weighed and dissolved in a sufficient volume of methanol with the aid of 15 min sonication and made up to 50 ml with the same to obtain 80µg/ml.

Preparation of Standard Solution of Atorvastatin (1.5×10⁻⁴ M): A quantity of about 8 mg of Atorvastatin was weighed and dissolved in a sufficient volume of methanol. It was made upto 50 ml with methanol to obtain a concentration of 160µg/ml.

Preparation of Standard Solution of Mixture (1.5×10⁻⁴ M): An accurately weighed quantity of

about 4 mg Mebendazole and 8mg of Atorvastatin were transferred to a 50 ml volumetric flask. It was dissolved and mixed thoroughly in methanol by sonication for 20 minutes and made up to 50 ml with methanol.

Validation of HPTLC Method: The method was validated as per ICH guidelines, and parameters like linearity, range, the limit of detection, the limit of quantification, precision, specificity, stability studies were performed.

Limit of Detection (LOD) and Limit of Quantification (LOQ): LOD & LOQ were calculated in terms of signal-to-noise ratio. The estimation was done using a set of five calibration curves used to determine method linearity.

$$\text{LOD} = 3 \sigma/S \text{ and } \text{LOQ} = 10\sigma/S$$

Where, σ = the standard deviation of y-intercepts of regression lines, S = the slope of the calibration curve.

Linearity and Range: The linearity of response was assessed by applying different volumes of stock solution viz, 2, 4, 6, 8, 10, 12 μ l on TLC plate to obtain linear concentration range of 0.04-0.24 μ g/spot of Mebendazole and 0.08-0.48 μ g/spot of Atorvastatin. The spots were developed and evaluated densitometrically using the CAMAG HPTLC system. Peak areas were noted for each spot and plotted against their respective concentrations to get a linear graph.

Precision: The precision of an analytical procedure expresses the closeness of agreement between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions. Precision may be considered at three levels: repeatability, intermediate precision, and reproducibility.

Intra-day Precision: Intra-day precision was studied by analyzing the standard drug of two different concentrations three times on the same day, and %RSD was calculated.

Inter-day Precision: Inter-day precision was studied by analyzing the standard drug of two different concentrations for three different days, and %RSD was calculated.

Repeatability:

Repeatability of Sample Application:

Repeatability of sample application was carried by spotting 6 times 10 μ l of drug solution on a pre-coated TLC plate followed by the development of plate and % RSD was calculated.

Repeatability of Sample Measurement:

The repeatability of sample application was determined by spotting 10 μ l of drug solution on a pre-coated TLC plate and developed the plate and scanned six times, and % RSD was calculated.

Specificity: Specificity is the ability to assess the analyte in the presence of components that are expected to be present.

The peak purity of Mebendazole and Atorvastatin was assessed by comparing its respective spectra at three different levels, that is, peak start(S), peak apex(M), and peak-end (E) positions of the spot.

Stability Studies: When the developed chromatographic plate is exposed to the atmosphere, the analytes are likely to decompose. It is necessary to study the stability of the drug on a plate.

It was studied by scanning the plate at a different time interval, and peak areas were compared with the peak area of the freshly scanned plate. The % change in the peak areas was calculated.

RESULTS AND DISCUSSION:

Method Development and Optimization: The selection of solvent is done based on the drug solubility and stability.

Accordingly, methanol was selected as the solvent. Different mobile phase compositions were tried for development and Validation of Mebendazole and Atorvastatin in combination by HPTLC method.

Among these trial mobile phase systems, Ethyl acetate: Toluene: Methanol (5:4:1 v/v/v) was selected as the compact and dense spots were obtained with good separation.

A wavelength of 280nm was fixed for scanning the plates since the response was good at this wavelength. A standard densitogram obtained is given in **Fig. 1**.




FIG. 1: DENSITOGAM OF MEBENDAZOLE 0.12µg/SPOT AND ATORVASTATIN 0.24µg/SPOT

Validation:

Linearity and Range: The linear regression data showed a good linear relationship over a concentration range of 0.04-0.24µg/spot of Mebendazole and 0.08-0.48µg/spot of Atorvastatin. The linear regression equation found for Mebendazole and Atorvastatin is presented in

Table 1. The peak areas of Mebendazole and Atorvastatin were noted with R_f values 0.65 ± 0.03 and 0.27 ± 0.03 , respectively.

The calibration graph obtained for Mebendazole and Atorvastatin is shown in Fig. 2 & 3. Overlain densitogram is given in Fig. 4.




FIG. 2: CALIBRATION GRAPH OF MEBENDAZOLE




FIG. 3: CALIBRATION GRAPH OF ATORVASTATIN




FIG. 4: OVERLAIN DENSITOGAMS OF MEBENDAZOLE AND ATORVASTATIN

Limit of Detection (LOD) and Limit of Quantification (LOQ): LOD and LOQ of the mixture were found to be 0.01 μ g/spot and 0.04 μ g/spot for Mebendazole; 0.02 μ g/spot and 0.08 μ g/spot for Atorvastatin respectively shown in **Table 1**.

TABLE 1: VALIDATION PARAMETERS FOR MEBENDAZOLE AND ATORVASTATIN

Parameters	Mebendazole	Atorvastatin
Linearity range	0.05 - 0.5 μ g/spot	0.08-0.48 μ g/spot
Regression equation	y = 8.160x +179.906	y = 9.118 x+294.28
Correlation coefficient	0.9978	0.9977
LOD	0.03 μ g/spot	0.05 μ g/spot
LOQ	0.045 μ g/spot	0.075 μ g/spot

Precision: Intraday, interday, repeatability of the sample application and measurement was carried out, and the % RSD values were found to be less

than 2 shows the precision of the method. The % RSD obtained is given in **Table 2**.

TABLE 2: PRECISION DATA

Application volume (μ L)	Precision							
	Interday precision		Intraday precision		Repeatability of the sample application		Repeatability of measurement	
	MBZ	ATV	MBZ	ATV	MBZ	ATV	MBZ	ATV
2	0.16	0.19	0.21	0.48	-	-	-	-
8	0.06	0.10	0.06	0.11	0.06	1.62	0.04	0.62
12	0.05	0.06	0.04	0.08	-	-	-	-

Specificity: The peak purity of both Mebendazole and Atorvastatin was assessed by comparing their respective spectra at peak start, peak apex, and peak end positions of the spot. The good correlation among the spectra acquired at the start (s), apex (m), and end (e) indicates the high purity of both drugs. It can be concluded that no impurities or degradation products migrated with the peaks obtained from standard solutions of the drugs.

Stability Studies: In the developed plate, Mebendazole was found to be stable for 15 min, and Levamisole was stable for 2 h.

Protein Binding Study of Mebendazole and Atorvastatin: About 2.5ml of 1.5×10^{-4} M Mebendazole solution and 1.5×10^{-4} M BSA solution were taken inside the previously activated dialysis membrane tubes and sealed. The tubes were immersed in 30ml of phosphate buffer taken in measuring cylinders. The samples were taken in replicates, and all the measuring cylinders were placed in a mechanical shaker at 40rpm for a sufficient period of time to complete dialysis.

The samples withdrawn from the buffer compartment at regular intervals were analyzed using the newly developed HPTLC technique. Similarly, protein binding studies were also conducted for Atorvastatin also.

Assessment of Protein Binding and Displacement Interaction Study: The *in-vitro* displacement interaction study was carried out for Mebendazole in the presence of its interacting drug Atorvastatin. About 2.5 ml of a standard solution of a mixture containing 1.5×10^{-4} M Mebendazole and 1.5×10^{-4} M Atorvastatin along with 1.5×10^{-4} M BSA were added to the previously activated dialysis membrane tubes and sealed. The tubes were immersed in 30ml of phosphate buffer taken in measuring cylinders. The samples were prepared in replicates, and all the measuring cylinders were placed in a mechanical shaker at 40rpm for a sufficient period to complete dialysis. The samples withdrawn from the buffer compartment at regular intervals were analyzed using the newly developed HPTLC technique. The results obtained are given in **Table 3**.

TABLE 3: RESULTS OF IN-VITRO INTERACTION STUDY OF MEBENDAZOLE AND ATORVASTATIN

Concentration (μ g/ml)		Concentration of unbound drug (μ g/ml)		% Protein binding		% Displacement	
MBZ	ATV	MBZ	ATV	MBZ	ATV	MBZ	ATV
80	160	12.3	8.94	84.42	94.8	15.58	5.2

The chromatograms were recorded, and the concentration of unbound drug was determined by calculating peak area ratios with the standards. The percentage of protein binding (F) was calculated as follows:

$$F = (B - A) / B \times 100$$

Where, A = Concentration of free drug in buffer compartment, B = Concentration of total drug in buffer compartment.

The percentage of protein binding (F) was calculated. The difference in the percentage protein binding of Mebendazole was calculated to find the percentage displacement of Mebendazole due to interaction with Atorvastatin.

The densitogram of Mebendazole and Atorvastatin admixture after equilibrium dialysis study for 6 h is given in **Fig. 5**.




FIG. 5: DENSITOGAM OF MEBENDAZOLE AND ATORVASTATIN ADMIXTURE AFTER EQUILIBRIUM DIALYSIS (6 h)

CONCLUSION: So far, no *in-vitro* interaction methods have been reported for the interaction of Mebendazole with Atorvastatin. Hence, this method was successfully employed for protein binding based *in-vitro* evaluation study of the same. From the protein binding study, a significant displacement was observed for Mebendazole and Atorvastatin. Hence their concomitant use should be avoided since it may lead to anaphylaxis and other severe hypersensitivity reactions. The immediate medical intervention of drug discontinuance is required if anaphylaxis of hypersensitivity reaction occurs. However, further *in-vitro* studies in animals and humans are requested for clinical decision making, choosing the appropriate treatment requirement, and eliminating drug-related problems. HPTLC methods developed were validated as per ICH guidelines and found to be specific, accurate, and precise. The newly developed HPTLC method might be an alternative step forward compared to the analytical methods available

ACKNOWLEDGEMENT: I greatly acknowledge Tamilnadu Pharmaceutical Sciences Welfare Trust

for providing Research Fellowship Award for this project work.

CONFLICTS OF INTEREST: Nil

REFERENCES:

1. Sonia K, Bhavya B and Lakshmi K: HPTLC Method development and Validation: An Overview. Journal of Pharmaceutical Sciences and Research 2017; 9(5): 652-657.
2. Jain A, Parashar A, Nema K and Narasinghani T: High Performance Thin Layer Chromatography (HPTLC): A Modern Analytical Tool for Chemical Analysis. Current Research in Pharmaceutical Sciences 2014; 04(01): 08-14.
3. Sethi PD: HPTLC: High Performance Liquid Chromatography, Quantitative Analysis of Pharmaceutical formulations. CBS Publishers and Distributors New Delhi 1997; 3-92.
4. Beckett AH and Stenlake JB: Practical pharmaceutical chemistry. CBS Publishers and Distributors New Delhi Edition 2005; 2: 279-81.
5. ICH harmonised tripartite guideline, validation of analytical procedures: Text and methodology. Q2 (R1), Geneva Switzerland 2005.
6. Shah U, Talaivya T and Gajjar A: Development and Validation of derivative spectroscopic method for the simultaneous Estimation of Mebendazole and Levamisole hydrochloride in pharmaceutical formulations. International Journal of Pharmaceutical Chemistry and Analysis 2015; 2(2): 108-12.

7. Xu L, Luan F, Wang L and Liu H: Development of a capillary zone electrophoresis method for determination of Mebendazole and Levamisole hydrochloride in a combined tablet and comparison with LC method. *Journal of AOAC International* 2014; 97(1): 128-32.
8. Rao K, Agarwal K, Pavami H and Mallikarjuna R: Analytical method development and validation for the simultaneous estimation of Levamisole and Mebendazole in bulk & tablet formulation by RP-HPLC method. *Indian J of Research in Pharmacy and Biotech* 2014; 2(1): 952-57.
9. Parakh R, Patil M, Sonawane S and Jain C: Development and Validation of spectrophotometric method for estimation of Mebendazole in bulk and pharmaceutical formulation. *World Journal of Pharmaceutical Research* 2015; 4(7): 2223-35.
10. Thangabalan B, Anusha G, Babu S and Kumar SB: RP-HPLC method development and validation of levamisole in pure and pharmaceutical formulation. *International J of Pharmacy and Analytical Research* 2017; 6(1): 101-107.
11. Patel B, Patel K, Patel G and Patel J: Development and Validation of HPTLC Method for Simultaneous Estimation of Levamisole Hydrochloride and Oxytocin in its Bulk and Pharmaceutical Dosage Form. *Austin Chromatography* 2017; 4(1): 1045.
12. Sangeetha R and Ravi TK: *In-vitro* Drug-Drug Interaction Studies of Apixaban with Atorvastatin by HPTLC Method. *J of Drug Metabolism and Toxicology* 2018; 9(3): 1-4
13. Pawluk S, Roels C, Wilby K and Ensom M: A Review of Pharmacokinetic Drug-Drug Interactions with the Anthelmintic Medications Albendazole and Mebendazole. *Clinical Pharmacokinetics* 2015; 1: 2-14.
14. Panchal and Suhagia B: Simultaneous analysis of atorvastatin calcium and losartan potassium in tablet dosage forms by RP-HPLC and HPTLC. *Acta Chromatographica* 2010; 22(2): 80-89.
15. Kumar L, Yadav Y and Rathnanand M: Simultaneous Determination of Linezolid and Levamisole Hydrochloride in a Fixed Dose Combination. *Indian Journal of Pharmaceutical Education and Research* 2017; 51(4): 613-19.
16. Kamat and Seetharamappa J: *In-vitro* study on the interaction BP of mechanism of tricyclic compounds with bovine serum albumin. *Journal of Pharmaceutical and Biomedical Analysis* 2004; 35: 655-64.
17. Qi Wang, Huang C, Jiang M, Ying-yao and Jie-hua Shi: Binding interaction of Atorvastatin with bovine serum albumin: Spectroscopic methods and molecular docking. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* 2016; 156: 155-63.
18. Dayan A: Albendazole, Mebendazole and Praziquantel- Review of non-clinical toxicity and pharmacokinetics. *Acta Tropica* 2003; 86: 141-59.
19. Indian pharmacopoeia. Controller of publications, New Delhi 2014; 1.
20. [www.drugbank.com.Availablefromhttps://www.drugbank.ca/drugs/DB00643](https://www.drugbank.ca/drugs/DB00643).
21. [www.drugbank.com.Availablefromhttps://www.drugbank.ca/drugs/DB01076](https://www.drugbank.ca/drugs/DB01076).

How to cite this article:

Thomas T, Manohari A and Ravi TK: HPTLC method development and validation for the *in-vitro* interaction study of Mebendazole with Atorvastatin. *Int J Pharm Sci & Res* 2021; 12(11): 5860-66. doi: 10.13040/IJPSR.0975-8232.12(11).5860-66.

All © 2021 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **Android OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)